In addition, sapatinib, in SW620 and SW620/Ad300 cell lines, reversed resistance to a similar magnitude as the ABCB1 transporter substrate, irinotecan, an anticancer drug used to treat colon cancer, whereas oxaliplatin, which is not an ABCB1 substrate, did not produce a significant effect (Table S1). Here, ABCB1 is linked to malignant colon neoplasm.